ID   LCK_HUMAN               Reviewed;         509 AA.
AC   P06239; D3DPP8; P07100; Q12850; Q13152; Q5TDH8; Q5TDH9; Q7RTZ3; Q96DW4;
AC   Q9NYT8;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 6.
DT   12-OCT-2022, entry version 270.
DE   RecName: Full=Tyrosine-protein kinase Lck;
DE            EC=2.7.10.2;
DE   AltName: Full=Leukocyte C-terminal Src kinase;
DE            Short=LSK;
DE   AltName: Full=Lymphocyte cell-specific protein-tyrosine kinase;
DE   AltName: Full=Protein YT16;
DE   AltName: Full=Proto-oncogene Lck;
DE   AltName: Full=T cell-specific protein-tyrosine kinase;
DE   AltName: Full=p56-LCK;
GN   Name=LCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3493153; DOI=10.1002/eji.1830161229;
RA   Koga Y., Caccia N., Toyonaga B., Spolski R., Yanagi Y., Yoshikai Y.,
RA   Mak T.W.;
RT   "A human T cell-specific cDNA clone (YT16) encodes a protein with extensive
RT   homology to a family of protein-tyrosine kinases.";
RL   Eur. J. Immunol. 16:1643-1646(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3265417; DOI=10.1002/jcb.240380206;
RA   Perlmutter R.M., Marth J.D., Lewis D.B., Peet R., Ziegler S.F.,
RA   Wilson C.B.;
RT   "Structure and expression of lck transcripts in human lymphoid cells.";
RL   J. Cell. Biochem. 38:117-126(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2558056; DOI=10.1016/0378-1119(89)90144-3;
RA   Rouer E., van Huynh T., de Souza S.L., Lang M.C., Fischer S., Benarous R.;
RT   "Structure of the human lck gene: differences in genomic organisation
RT   within src-related genes affect only N-terminal exons.";
RL   Gene 84:105-113(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS LEU-28; GLN-LYS-PRO-232 INS; VAL-353
RP   AND LEU-447, AND PHOSPHORYLATION AT TYR-394 AND TYR-505.
RC   TISSUE=Leukemia;
RX   PubMed=8139546; DOI=10.1128/mcb.14.4.2429-2437.1994;
RA   Wright D.D., Sefton B.M., Kamps M.P.;
RT   "Oncogenic activation of the Lck protein accompanies translocation of the
RT   LCK gene in the human HSB2 T-cell leukemia.";
RL   Mol. Cell. Biol. 14:2429-2437(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ALTERNATIVE SPLICING.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=7495859; DOI=10.1016/0167-4781(95)00162-a;
RA   Vogel L.B., Arthur R., Fujita D.J.;
RT   "An aberrant lck mRNA in two human T-cell lines.";
RL   Biochim. Biophys. Acta 1264:168-172(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12401726; DOI=10.2337/diabetes.51.11.3326;
RA   Nervi S., Nicodeme S., Gartioux C., Atlan C., Lathrop M., Reviron D.,
RA   Naquet P., Matsuda F., Imbert J., Vialettes B.;
RT   "No association between lck gene polymorphisms and protein level in type 1
RT   diabetes.";
RL   Diabetes 51:3326-3330(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-35.
RX   PubMed=2850479; DOI=10.1128/mcb.8.8.3058-3064.1988;
RA   Garvin A.M., Pawar S., Marth J.D., Perlmutter R.M.;
RT   "Structure of the murine lck gene and its rearrangement in a murine
RT   lymphoma cell line.";
RL   Mol. Cell. Biol. 8:3058-3064(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-35.
RX   PubMed=2787474; DOI=10.1128/mcb.9.5.2173-2180.1989;
RA   Takadera T., Leung S., Gernone A., Koga Y., Takihara Y., Miyamoto N.G.,
RA   Mak T.W.;
RT   "Structure of the two promoters of the human lck gene: differential
RT   accumulation of two classes of lck transcripts in T cells.";
RL   Mol. Cell. Biol. 9:2173-2180(1989).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-509.
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=11009097;
RX   DOI=10.1002/1521-4141(200009)30:9<2632::aid-immu2632>3.0.co;2-c;
RA   Boncristiano M., Majolini M.B., D'Elios M.M., Pacini S., Valensin S.,
RA   Ulivieri C., Amedei A., Falini B., Del Prete G., Telford J.L.,
RA   Baldari C.T.;
RT   "Defective recruitment and activation of ZAP-70 in common variable
RT   immunodeficiency patients with T cell defects.";
RL   Eur. J. Immunol. 30:2632-2638(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-509.
RX   PubMed=2835736;
RA   Veillette A., Foss F.M., Sausville E.A., Bolen J.B., Rosen N.;
RT   "Expression of the lck tyrosine kinase gene in human colon carcinoma and
RT   other non-lymphoid human tumor cell lines.";
RL   Oncogene Res. 1:357-374(1987).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 375-509.
RX   PubMed=3489486; DOI=10.1016/0167-4889(86)90228-4;
RA   Trevillyan J.M., Lin Y., Chen S.J., Phillips C.A., Canna C., Linna T.J.;
RT   "Human T lymphocytes express a protein-tyrosine kinase homologous to
RT   p56LSTRA.";
RL   Biochim. Biophys. Acta 888:286-295(1986).
RN   [15]
RP   PHOSPHORYLATION AT TYR-505.
RX   PubMed=1639064; DOI=10.1002/j.1460-2075.1992.tb05361.x;
RA   Bergman M., Mustelin T., Oetken C., Partanen J., Flint N.A., Amrein K.E.,
RA   Autero M., Burn P., Alitalo K.;
RT   "The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down
RT   regulates its catalytic activity.";
RL   EMBO J. 11:2919-2924(1992).
RN   [16]
RP   INTERACTION WITH PI3K.
RX   PubMed=7504174; DOI=10.1128/mcb.13.12.7408-7417.1993;
RA   Vogel L.B., Fujita D.J.;
RT   "The SH3 domain of p56lck is involved in binding to phosphatidylinositol
RT   3'-kinase from T lymphocytes.";
RL   Mol. Cell. Biol. 13:7408-7417(1993).
RN   [17]
RP   INTERACTION WITH KHDRBS1.
RX   PubMed=7852312; DOI=10.1074/jbc.270.6.2506;
RA   Vogel L.B., Fujita D.J.;
RT   "p70 phosphorylation and binding to p56lck is an early event in
RT   interleukin-2-induced onset of cell cycle progression in T-lymphocytes.";
RL   J. Biol. Chem. 270:2506-2511(1995).
RN   [18]
RP   INTERACTION WITH SQSTM1, AND MUTAGENESIS OF SER-59 AND ARG-154.
RX   PubMed=8618896; DOI=10.1073/pnas.92.26.12338;
RA   Park I., Chung J., Walsh C.T., Yun Y., Strominger J.L., Shin J.;
RT   "Phosphotyrosine-independent binding of a 62-kDa protein to the src
RT   homology 2 (SH2) domain of p56lck and its regulation by phosphorylation of
RT   Ser-59 in the lck unique N-terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:12338-12342(1995).
RN   [19]
RP   PHOSPHORYLATION AT TYR-505 BY CSK, AND AUTOPHOSPHORYLATION.
RX   PubMed=8631775; DOI=10.1074/jbc.271.13.7465;
RA   Bougeret C., Delaunay T., Romero F., Jullien P., Sabe H., Hanafusa H.,
RA   Benarous R., Fischer S.;
RT   "Detection of a physical and functional interaction between Csk and Lck
RT   which involves the SH2 domain of Csk and is mediated by autophosphorylation
RT   of Lck on tyrosine 394.";
RL   J. Biol. Chem. 271:7465-7472(1996).
RN   [20]
RP   INTERACTION WITH HIV-1 NEF (MICROBIAL INFECTION).
RX   PubMed=8794306; DOI=10.1128/jvi.70.10.6701-6708.1996;
RA   Greenway A.L., Azad A., Mills J., McPhee D.A.;
RT   "Human immunodeficiency virus type 1 Nef binds directly to LCK and mitogen-
RT   activated protein kinase, inhibiting kinase activity.";
RL   J. Virol. 70:6701-6708(1996).
RN   [21]
RP   INTERACTION WITH AXL.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [22]
RP   REVIEW.
RX   PubMed=10848956; DOI=10.1046/j.1432-1327.2000.01412.x;
RA   Isakov N., Biesinger B.;
RT   "Lck protein tyrosine kinase is a key regulator of T-cell activation and a
RT   target for signal intervention by Herpesvirus saimiri and other viral gene
RT   products.";
RL   Eur. J. Biochem. 267:3413-3421(2000).
RN   [23]
RP   INTERACTION WITH CD48.
RX   PubMed=12007789; DOI=10.1016/s0167-4889(02)00165-9;
RA   Hawash I.Y., Hu X.E., Adal A., Cassady J.M., Geahlen R.L., Harrison M.L.;
RT   "The oxygen-substituted palmitic acid analogue, 13-oxypalmitic acid,
RT   inhibits Lck localization to lipid rafts and T cell signaling.";
RL   Biochim. Biophys. Acta 1589:140-150(2002).
RN   [24]
RP   SUBUNIT, AND INTERACTION WITH CD160.
RX   PubMed=11978774; DOI=10.1093/intimm/14.5.445;
RA   Nikolova M., Marie-Cardine A., Boumsell L., Bensussan A.;
RT   "BY55/CD160 acts as a co-receptor in TCR signal transduction of a human
RT   circulating cytotoxic effector T lymphocyte subset lacking CD28
RT   expression.";
RL   Int. Immunol. 14:445-451(2002).
RN   [25]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12218089; DOI=10.4049/jimmunol.169.6.2813;
RA   Yasuda K., Nagafuku M., Shima T., Okada M., Yagi T., Yamada T., Minaki Y.,
RA   Kato A., Tani-Ichi S., Hamaoka T., Kosugi A.;
RT   "Fyn is essential for tyrosine phosphorylation of Csk-binding
RT   protein/phosphoprotein associated with glycolipid-enriched microdomains in
RT   lipid rafts in resting T cells.";
RL   J. Immunol. 169:2813-2817(2002).
RN   [26]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::aid-prot212>3.0.co;2-h;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line protein
RT   expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [27]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610046; DOI=10.1084/jem.20031484;
RA   Brdickova N., Brdicka T., Angelisova P., Horvath O., Spicka J., Hilgert I.,
RA   Paces J., Simeoni L., Kliche S., Merten C., Schraven B., Horejsi V.;
RT   "LIME: a new membrane raft-associated adaptor protein involved in CD4 and
RT   CD8 coreceptor signaling.";
RL   J. Exp. Med. 198:1453-1462(2003).
RN   [28]
RP   INTERACTION WITH LIME1.
RX   PubMed=14610044; DOI=10.1084/jem.20030232;
RA   Hur E.M., Son M., Lee O.-H., Choi Y.B., Park C., Lee H., Yun Y.;
RT   "LIME, a novel transmembrane adaptor protein, associates with p56lck and
RT   mediates T cell activation.";
RL   J. Exp. Med. 198:1463-1473(2003).
RN   [29]
RP   INTERACTION WITH PTPRH.
RX   PubMed=12837766; DOI=10.1074/jbc.m300648200;
RA   Ito T., Okazawa H., Maruyama K., Tomizawa K., Motegi S., Ohnishi H.,
RA   Kuwano H., Kosugi A., Matozaki T.;
RT   "Interaction of SAP-1, a transmembrane-type protein-tyrosine phosphatase,
RT   with the tyrosine kinase Lck. Roles in regulation of T cell function.";
RL   J. Biol. Chem. 278:34854-34863(2003).
RN   [30]
RP   INTERACTION WITH UNC119.
RX   PubMed=14757743; DOI=10.1084/jem.20030589;
RA   Gorska M.M., Stafford S.J., Cen O., Sur S., Alam R.;
RT   "Unc119, a novel activator of Lck/Fyn, is essential for T cell
RT   activation.";
RL   J. Exp. Med. 199:369-379(2004).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION OF ZAP70.
RX   PubMed=16339550; DOI=10.4049/jimmunol.175.12.8123;
RA   Gelkop S., Gish G.D., Babichev Y., Pawson T., Isakov N.;
RT   "T cell activation-induced CrkII binding to the Zap70 protein tyrosine
RT   kinase is mediated by Lck-dependent phosphorylation of Zap70 tyrosine
RT   315.";
RL   J. Immunol. 175:8123-8132(2005).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [33]
RP   DEPHOSPHORYLATION BY PTN22.
RX   PubMed=16461343; DOI=10.1074/jbc.m600498200;
RA   Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J.,
RA   Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J., Clark J.M.;
RT   "Identification of substrates of human protein-tyrosine phosphatase
RT   PTPN22.";
RL   J. Biol. Chem. 281:11002-11010(2006).
RN   [34]
RP   FUNCTION IN PHOSPHORYLATION OF TYROBP.
RX   PubMed=16709819; DOI=10.4049/jimmunol.176.11.6615;
RA   Mason L.H., Willette-Brown J., Taylor L.S., McVicar D.W.;
RT   "Regulation of Ly49D/DAP12 signal transduction by Src-family kinases and
RT   CD45.";
RL   J. Immunol. 176:6615-6623(2006).
RN   [35]
RP   INTERACTION WITH EPHA1; PTK2B AND PI3-KINASE.
RX   PubMed=17634955; DOI=10.1002/eji.200737111;
RA   Hjorthaug H.S., Aasheim H.C.;
RT   "Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes.";
RL   Eur. J. Immunol. 37:2326-2336(2007).
RN   [36]
RP   INTERACTION WITH CEACAM1.
RX   PubMed=18424730; DOI=10.4049/jimmunol.180.9.6085;
RA   Chen Z., Chen L., Qiao S.W., Nagaishi T., Blumberg R.S.;
RT   "Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits
RT   proximal TCR signaling by targeting ZAP-70.";
RL   J. Immunol. 180:6085-6093(2008).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-102; THR-159; SER-162;
RP   SER-194 AND TYR-505, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF RUNX3.
RX   PubMed=20100835; DOI=10.1074/jbc.m109.071381;
RA   Goh Y.M., Cinghu S., Hong E.T., Lee Y.S., Kim J.H., Jang J.W., Li Y.H.,
RA   Chi X.Z., Lee K.S., Wee H., Ito Y., Oh B.C., Bae S.C.;
RT   "Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the
RT   protein in the cytoplasm.";
RL   J. Biol. Chem. 285:10122-10129(2010).
RN   [41]
RP   FUNCTION IN PTK2B/PYK2 PHOSPHORYLATION.
RX   PubMed=20028775; DOI=10.1189/jlb.0409227;
RA   Collins M., Tremblay M., Chapman N., Curtiss M., Rothman P.B.,
RA   Houtman J.C.;
RT   "The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580
RT   occurs via a distinct mechanism than other receptor systems.";
RL   J. Leukoc. Biol. 87:691-701(2010).
RN   [42]
RP   FUNCTION IN PHOSPHORYLATION OF RHOH.
RX   PubMed=20851766; DOI=10.1016/j.cellsig.2010.09.009;
RA   Wang H., Zeng X., Fan Z., Lim B.;
RT   "RhoH modulates pre-TCR and TCR signalling by regulating LCK.";
RL   Cell. Signal. 23:249-258(2011).
RN   [43]
RP   FUNCTION IN TCR SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION AT
RP   TYR-394 BY PTPN2.
RX   PubMed=22080863; DOI=10.1172/jci59492;
RA   Wiede F., Shields B.J., Chew S.H., Kyparissoudis K., van Vliet C.,
RA   Galic S., Tremblay M.L., Russell S.M., Godfrey D.I., Tiganis T.;
RT   "T cell protein tyrosine phosphatase attenuates T cell signaling to
RT   maintain tolerance in mice.";
RL   J. Clin. Invest. 121:4758-4774(2011).
RN   [44]
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND PALMITOYLATION.
RX   PubMed=22034844; DOI=10.3109/09687688.2011.630682;
RA   Zeidman R., Buckland G., Cebecauer M., Eissmann P., Davis D.M., Magee A.I.;
RT   "DHHC2 is a protein S-acyltransferase for Lck.";
RL   Mol. Membr. Biol. 28:473-486(2011).
RN   [45]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT.
RX   PubMed=21269457; DOI=10.1186/1750-1326-6-12;
RA   Scales T.M., Derkinderen P., Leung K.Y., Byers H.L., Ward M.A., Price C.,
RA   Bird I.N., Perera T., Kellie S., Williamson R., Anderton B.H.,
RA   Reynolds C.H.;
RT   "Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn.";
RL   Mol. Neurodegener. 6:12-12(2011).
RN   [46]
RP   ACTIVITY REGULATION.
RX   PubMed=21917715; DOI=10.1126/scisignal.2001893;
RA   Schoenborn J.R., Tan Y.X., Zhang C., Shokat K.M., Weiss A.;
RT   "Feedback circuits monitor and adjust Basal lck-dependent events in T cell
RT   receptor signaling.";
RL   Sci. Signal. 4:RA59-RA59(2011).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-505, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [48]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL46 (MICROBIAL INFECTION).
RX   PubMed=23946459; DOI=10.1128/jvi.01702-13;
RA   Strunk U., Saffran H.A., Wu F.W., Smiley J.R.;
RT   "Role of herpes simplex virus VP11/12 tyrosine-based motifs in binding and
RT   activation of the Src family kinase Lck and recruitment of p85, Grb2, and
RT   Shc.";
RL   J. Virol. 87:11276-11286(2013).
RN   [49]
RP   INTERACTION WITH FYB2 AND FYB1.
RX   PubMed=27335501; DOI=10.4049/jimmunol.1501913;
RA   Jung S.H., Yoo E.H., Yu M.J., Song H.M., Kang H.Y., Cho J.Y., Lee J.R.;
RT   "ARAP, a novel adaptor protein, is required for TCR signaling and integrin-
RT   mediated adhesion.";
RL   J. Immunol. 197:942-952(2016).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 53-226.
RX   PubMed=7512222; DOI=10.1038/368764a0;
RA   Eck M.J., Atweell S.K., Shoelson S.E., Harrison S.C.;
RT   "Structure of the regulatory domains of the Src-family tyrosine kinase
RT   Lck.";
RL   Nature 368:764-769(1994).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 127-221.
RX   PubMed=7532720; DOI=10.1006/jmbi.1994.0089;
RA   Mikol V., Baumann G., Keller T.H., Manning U.M., Zurini M.G.M.;
RT   "The crystal structures of the SH2 domain of p56lck complexed with two
RT   phosphonopeptides suggest a gated peptide binding site.";
RL   J. Mol. Biol. 246:344-355(1995).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.0 ANGSTROMS) OF 122-226.
RX   PubMed=8604142; DOI=10.1006/jmbi.1996.0112;
RA   Tong L., Warren T.C., King J., Betageri R., Rose J., Jakes S.;
RT   "Crystal structures of the human p56lck SH2 domain in complex with two
RT   short phosphotyrosyl peptides at 1.0-A and 1.8-A resolution.";
RL   J. Mol. Biol. 256:601-610(1996).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 231-501.
RX   PubMed=8945479; DOI=10.1038/384484a0;
RA   Yamaguchi H., Hendrickson W.A.;
RT   "Structural basis for activation of human lymphocyte kinase Lck upon
RT   tyrosine phosphorylation.";
RL   Nature 384:484-489(1996).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 119-226.
RX   PubMed=9685372; DOI=10.1074/jbc.273.32.20238;
RA   Tong L., Warren T.C., Lukas S., Schembri-King J., Betageri R.,
RA   Proudfoot J.R., Jakes S.;
RT   "Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2
RT   domain binding.";
RL   J. Biol. Chem. 273:20238-20242(1998).
RN   [55]
RP   VARIANT IMD22 PRO-341.
RX   PubMed=22985903; DOI=10.1016/j.jaci.2012.07.029;
RA   Hauck F., Randriamampita C., Martin E., Gerart S., Lambert N., Lim A.,
RA   Soulier J., Maciorowski Z., Touzot F., Moshous D., Quartier P.,
RA   Heritier S., Blanche S., Rieux-Laucat F., Brousse N., Callebaut I.,
RA   Veillette A., Hivroz C., Fischer A., Latour S., Picard C.;
RT   "Primary T-cell immunodeficiency with immunodysregulation caused by
RT   autosomal recessive LCK deficiency.";
RL   J. Allergy Clin. Immunol. 130:1144-1152(2012).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays an essential
CC       role in the selection and maturation of developing T-cells in the
CC       thymus and in the function of mature T-cells. Plays a key role in T-
CC       cell antigen receptor (TCR)-linked signal transduction pathways.
CC       Constitutively associated with the cytoplasmic portions of the CD4 and
CC       CD8 surface receptors. Association of the TCR with a peptide antigen-
CC       bound MHC complex facilitates the interaction of CD4 and CD8 with MHC
CC       class II and class I molecules, respectively, thereby recruiting the
CC       associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then
CC       phosphorylates tyrosine residues within the immunoreceptor tyrosine-
CC       based activation motifs (ITAM) of the cytoplasmic tails of the TCR-
CC       gamma chains and CD3 subunits, initiating the TCR/CD3 signaling
CC       pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70,
CC       that becomes phosphorylated and activated by LCK. Following this, a
CC       large number of signaling molecules are recruited, ultimately leading
CC       to lymphokine production. LCK also contributes to signaling by other
CC       receptor molecules. Associates directly with the cytoplasmic tail of
CC       CD2, which leads to hyperphosphorylation and activation of LCK. Also
CC       plays a role in the IL2 receptor-linked signaling pathway that controls
CC       the T-cell proliferative response. Binding of IL2 to its receptor
CC       results in increased activity of LCK. Is expressed at all stages of
CC       thymocyte development and is required for the regulation of maturation
CC       events that are governed by both pre-TCR and mature alpha beta TCR.
CC       Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the
CC       microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with
CC       FYB2 (PubMed:27335501). {ECO:0000269|PubMed:16339550,
CC       ECO:0000269|PubMed:16709819, ECO:0000269|PubMed:20028775,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20851766,
CC       ECO:0000269|PubMed:21269457, ECO:0000269|PubMed:22080863,
CC       ECO:0000269|PubMed:27335501}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- ACTIVITY REGULATION: The relative activities of the inhibitory
CC       tyrosine-protein kinase CSK and the activating tyrosine-protein
CC       phosphatase PTPRC/CD45 determine the level of LCK activity. These
CC       interactions allow rapid and efficient activation of LCK in response to
CC       TCR stimulation. {ECO:0000269|PubMed:21917715}.
CC   -!- SUBUNIT: Binds to the cytoplasmic domain of cell surface receptors,
CC       such as AXL, CD2, CD4, CD5, CD8, CD44, CD45 and CD122. Also binds to
CC       effector molecules, such as PI4K, VAV1, RASA1, FYB1 and to other
CC       protein kinases including CDK1, RAF1, ZAP70 and SYK. Binds to
CC       phosphatidylinositol 3'-kinase (PI3K) from T-lymphocytes through its
CC       SH3 domain and to the tyrosine phosphorylated form of KHDRBS1/p70
CC       through its SH2 domain. This interaction inhibits its tyrosine-kinase
CC       activity. Interacts with SQSTM1. Interacts with phosphorylated LIME1.
CC       Interacts with CBLB and PTPRH. Interacts with RUNX3. Forms a signaling
CC       complex with EPHA1, PTK2B and PI3-KINASE; upon activation by EFNA1
CC       which may regulate T-lymphocyte migration. Associates with ZAP70 and
CC       RHOH; these interactions allow LCK-mediated RHOH and CD3 subunit
CC       phosphorylation in the presence of functional ZAP70. Interacts with
CC       UNC119; this interaction plays a crucial role in activation of LCK.
CC       Interacts with CEACAM1 (via cytoplasmic domain); mediates CEACAM1
CC       phosphorylation resulting in PTPN6 recruitment that dephosphorylates
CC       TCR stimulation-induced CD247 and ZAP70 (PubMed:18424730). Interacts
CC       with CD160. Interacts with CD48 (PubMed:12007789).
CC       {ECO:0000269|PubMed:11978774, ECO:0000269|PubMed:12007789,
CC       ECO:0000269|PubMed:12837766, ECO:0000269|PubMed:14610044,
CC       ECO:0000269|PubMed:14610046, ECO:0000269|PubMed:14757743,
CC       ECO:0000269|PubMed:17634955, ECO:0000269|PubMed:18424730,
CC       ECO:0000269|PubMed:7504174, ECO:0000269|PubMed:7852312,
CC       ECO:0000269|PubMed:8618896, ECO:0000269|PubMed:9178760}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1
CC       UL46; this interaction activates LCK. {ECO:0000269|PubMed:23946459}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Nef through its SH3
CC       domain. {ECO:0000269|PubMed:8794306}.
CC   -!- INTERACTION:
CC       P06239; O14672: ADAM10; NbExp=3; IntAct=EBI-1348, EBI-1536151;
CC       P06239; Q13444: ADAM15; NbExp=4; IntAct=EBI-1348, EBI-77818;
CC       P06239; P10275: AR; NbExp=7; IntAct=EBI-1348, EBI-608057;
CC       P06239; P20749: BCL3; NbExp=3; IntAct=EBI-1348, EBI-958997;
CC       P06239; P01730: CD4; NbExp=2; IntAct=EBI-1348, EBI-353826;
CC       P06239; Q5VV42: CDKAL1; NbExp=3; IntAct=EBI-1348, EBI-10194801;
CC       P06239; P36888: FLT3; NbExp=2; IntAct=EBI-1348, EBI-3946257;
CC       P06239; Q13480: GAB1; NbExp=10; IntAct=EBI-1348, EBI-517684;
CC       P06239; P23771: GATA3; NbExp=3; IntAct=EBI-1348, EBI-6664760;
CC       P06239; P07900: HSP90AA1; NbExp=3; IntAct=EBI-1348, EBI-296047;
CC       P06239; P08238: HSP90AB1; NbExp=4; IntAct=EBI-1348, EBI-352572;
CC       P06239; Q07666: KHDRBS1; NbExp=5; IntAct=EBI-1348, EBI-1364;
CC       P06239; P10721: KIT; NbExp=8; IntAct=EBI-1348, EBI-1379503;
CC       P06239; O43561: LAT; NbExp=2; IntAct=EBI-1348, EBI-1222766;
CC       P06239; P06239: LCK; NbExp=5; IntAct=EBI-1348, EBI-1348;
CC       P06239; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1348, EBI-741037;
CC       P06239; Q9H204: MED28; NbExp=4; IntAct=EBI-1348, EBI-514199;
CC       P06239; P08581: MET; NbExp=3; IntAct=EBI-1348, EBI-1039152;
CC       P06239; P04150: NR3C1; NbExp=3; IntAct=EBI-1348, EBI-493507;
CC       P06239; Q04759: PRKCQ; NbExp=2; IntAct=EBI-1348, EBI-374762;
CC       P06239; Q9Y2R2: PTPN22; NbExp=6; IntAct=EBI-1348, EBI-1211241;
CC       P06239; P29350: PTPN6; NbExp=5; IntAct=EBI-1348, EBI-78260;
CC       P06239; P08575: PTPRC; NbExp=7; IntAct=EBI-1348, EBI-1341;
CC       P06239; Q9NP31: SH2D2A; NbExp=12; IntAct=EBI-1348, EBI-490630;
CC       P06239; P43405: SYK; NbExp=7; IntAct=EBI-1348, EBI-78302;
CC       P06239; Q8N1K5-1: THEMIS; NbExp=3; IntAct=EBI-1348, EBI-15102259;
CC       P06239; P0CG48: UBC; NbExp=2; IntAct=EBI-1348, EBI-3390054;
CC       P06239; P43403: ZAP70; NbExp=2; IntAct=EBI-1348, EBI-1211276;
CC       P06239; P22575; Xeno; NbExp=7; IntAct=EBI-1348, EBI-866709;
CC       P06239; Q9YJQ8; Xeno; NbExp=2; IntAct=EBI-1348, EBI-7709835;
CC       P06239-3; Q96DX5: ASB9; NbExp=3; IntAct=EBI-13287659, EBI-745641;
CC       P06239-3; Q9BXJ5: C1QTNF2; NbExp=3; IntAct=EBI-13287659, EBI-2817707;
CC       P06239-3; Q9GZU7: CTDSP1; NbExp=3; IntAct=EBI-13287659, EBI-751587;
CC       P06239-3; A8MTA8-2: FAM166B; NbExp=3; IntAct=EBI-13287659, EBI-12160437;
CC       P06239-3; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-13287659, EBI-10271199;
CC       P06239-3; I6L996: PTK2; NbExp=3; IntAct=EBI-13287659, EBI-10181089;
CC       P06239-3; Q92753-1: RORB; NbExp=3; IntAct=EBI-13287659, EBI-18560266;
CC       P06239-3; Q9UPQ4-2: TRIM35; NbExp=3; IntAct=EBI-13287659, EBI-17716262;
CC       P06239-3; Q5T6F2: UBAP2; NbExp=3; IntAct=EBI-13287659, EBI-2514383;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12218089,
CC       ECO:0000269|PubMed:22034844}; Lipid-anchor
CC       {ECO:0000269|PubMed:12218089, ECO:0000269|PubMed:22034844}; Cytoplasmic
CC       side {ECO:0000269|PubMed:12218089, ECO:0000269|PubMed:22034844}.
CC       Cytoplasm, cytosol {ECO:0000269|PubMed:12218089,
CC       ECO:0000269|PubMed:22034844}. Note=Present in lipid rafts in an
CC       inactive form. {ECO:0000269|PubMed:12218089}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=P06239-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P06239-2; Sequence=VSP_005000, VSP_005001;
CC       Name=3;
CC         IsoId=P06239-3; Sequence=VSP_016049;
CC   -!- TISSUE SPECIFICITY: Expressed specifically in lymphoid cells.
CC   -!- DOMAIN: The SH2 domain mediates interaction with SQSTM1. Interaction is
CC       regulated by Ser-59 phosphorylation.
CC   -!- PTM: Autophosphorylated on Tyr-394, increasing enzymatic activity, this
CC       site is dephosphorylated by PTN22. Phosphorylated on Tyr-505 by CSK,
CC       decreasing activity. Dephosphorylated by PTPRC/CD45. Dephosphorylation
CC       at Tyr-394 by PTPN2 negatively regulates T-cell receptor signaling.
CC       {ECO:0000269|PubMed:1639064, ECO:0000269|PubMed:22080863,
CC       ECO:0000269|PubMed:8139546, ECO:0000269|PubMed:8631775}.
CC   -!- PTM: Myristoylation is required prior to palmitoylation. {ECO:0000250}.
CC   -!- PTM: Palmitoylation regulates association with the plasma membrane and
CC       could be mediated by ZDHHC2. {ECO:0000269|PubMed:22034844}.
CC   -!- MASS SPECTROMETRY: Mass=57869.42; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:11840567};
CC   -!- DISEASE: Note=A chromosomal aberration involving LCK is found in
CC       leukemias. Translocation t(1;7)(p34;q34) with TCRB.
CC   -!- DISEASE: Immunodeficiency 22 (IMD22) [MIM:615758]: A primary
CC       immunodeficiency characterized by T-cell dysfunction. Affected
CC       individuals present with lymphopenia, recurrent infections, severe
CC       diarrhea, and failure to thrive. {ECO:0000269|PubMed:22985903}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LCKID14ch1p34.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Lck entry;
CC       URL="https://en.wikipedia.org/wiki/Lck";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X05027; CAA28691.1; -; mRNA.
DR   EMBL; X13529; CAA31884.1; -; mRNA.
DR   EMBL; M36881; AAA59502.1; -; mRNA.
DR   EMBL; X14055; CAA32211.1; -; Genomic_DNA.
DR   EMBL; X14053; CAA32211.1; JOINED; Genomic_DNA.
DR   EMBL; X14054; CAA32211.1; JOINED; Genomic_DNA.
DR   EMBL; U07236; AAA18225.1; -; mRNA.
DR   EMBL; U23852; AAC50287.1; -; mRNA.
DR   EMBL; BN000073; CAD55807.1; -; Genomic_DNA.
DR   EMBL; AL121991; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX07543.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07546.1; -; Genomic_DNA.
DR   EMBL; BC013200; AAH13200.1; -; mRNA.
DR   EMBL; M21510; AAA59501.1; ALT_TERM; Genomic_DNA.
DR   EMBL; M26692; AAA59503.1; -; Genomic_DNA.
DR   EMBL; AF228313; AAF34794.1; -; mRNA.
DR   EMBL; X06369; CAA29667.1; -; mRNA.
DR   EMBL; X04476; CAA28165.1; -; mRNA.
DR   CCDS; CCDS359.1; -. [P06239-1]
DR   PIR; JQ0152; OKHULK.
DR   RefSeq; NP_001036236.1; NM_001042771.2. [P06239-1]
DR   RefSeq; NP_005347.3; NM_005356.4. [P06239-1]
DR   PDB; 1BHF; X-ray; 1.80 A; A=119-226.
DR   PDB; 1BHH; X-ray; 1.90 A; A=119-226, B=124-226.
DR   PDB; 1CWD; X-ray; 2.25 A; L=127-222.
DR   PDB; 1CWE; X-ray; 2.30 A; A/C=127-222.
DR   PDB; 1FBZ; X-ray; 2.40 A; A/B=123-226.
DR   PDB; 1H92; NMR; -; A=59-120.
DR   PDB; 1IJR; X-ray; 2.20 A; A=124-226.
DR   PDB; 1KIK; NMR; -; A=64-120.
DR   PDB; 1LCJ; X-ray; 1.80 A; A=119-226.
DR   PDB; 1LCK; X-ray; 2.50 A; A=53-226, B=502-509.
DR   PDB; 1LKK; X-ray; 1.00 A; A=122-226.
DR   PDB; 1LKL; X-ray; 1.80 A; A=123-226.
DR   PDB; 1Q68; NMR; -; B=7-35.
DR   PDB; 1Q69; NMR; -; B=7-35.
DR   PDB; 1QPC; X-ray; 1.60 A; A=231-509.
DR   PDB; 1QPD; X-ray; 2.00 A; A=231-509.
DR   PDB; 1QPE; X-ray; 2.00 A; A=231-509.
DR   PDB; 1QPJ; X-ray; 2.20 A; A=231-509.
DR   PDB; 1X27; X-ray; 2.70 A; A/B/C/D/E/F=64-226.
DR   PDB; 2IIM; X-ray; 1.00 A; A=59-119.
DR   PDB; 2OF2; X-ray; 2.00 A; A=231-501.
DR   PDB; 2OF4; X-ray; 2.70 A; A=231-501.
DR   PDB; 2OFU; X-ray; 2.00 A; A=229-501.
DR   PDB; 2OFV; X-ray; 2.00 A; A/B=232-498.
DR   PDB; 2OG8; X-ray; 2.30 A; A/B=237-499.
DR   PDB; 2PL0; X-ray; 2.80 A; A=225-509.
DR   PDB; 2ZM1; X-ray; 2.10 A; A=225-509.
DR   PDB; 2ZM4; X-ray; 2.70 A; A=225-509.
DR   PDB; 2ZYB; X-ray; 2.55 A; A=225-509.
DR   PDB; 3AC1; X-ray; 1.99 A; A=225-509.
DR   PDB; 3AC2; X-ray; 2.10 A; A=225-509.
DR   PDB; 3AC3; X-ray; 2.55 A; A=225-509.
DR   PDB; 3AC4; X-ray; 2.70 A; A=225-509.
DR   PDB; 3AC5; X-ray; 2.50 A; A=225-509.
DR   PDB; 3AC8; X-ray; 2.30 A; A=225-509.
DR   PDB; 3ACJ; X-ray; 2.20 A; A=225-509.
DR   PDB; 3ACK; X-ray; 2.60 A; A=225-509.
DR   PDB; 3AD4; X-ray; 2.20 A; A=225-509.
DR   PDB; 3AD5; X-ray; 2.00 A; A=225-509.
DR   PDB; 3AD6; X-ray; 2.15 A; A=225-509.
DR   PDB; 3B2W; X-ray; 2.30 A; A=226-502.
DR   PDB; 3BRH; X-ray; 2.20 A; C/D=391-397.
DR   PDB; 3BYM; X-ray; 2.00 A; A=230-501.
DR   PDB; 3BYO; X-ray; 2.00 A; A=231-501.
DR   PDB; 3BYS; X-ray; 2.20 A; A=225-501.
DR   PDB; 3BYU; X-ray; 2.30 A; A=225-501.
DR   PDB; 3KMM; X-ray; 2.80 A; A=229-509.
DR   PDB; 3KXZ; X-ray; 2.37 A; A=225-509.
DR   PDB; 3LCK; X-ray; 1.70 A; A=231-501.
DR   PDB; 3MPM; X-ray; 1.95 A; A=237-501.
DR   PDB; 4C3F; X-ray; 1.72 A; A=237-501.
DR   PDB; 4D8K; X-ray; 2.36 A; A=53-226.
DR   PDB; 5MTM; X-ray; 2.40 A; A=118-231.
DR   PDB; 5MTN; X-ray; 2.85 A; A=118-231.
DR   PDB; 6H6A; X-ray; 2.00 A; E/H/K=2-11.
DR   PDB; 6PDJ; X-ray; 1.81 A; A=225-509.
DR   PDBsum; 1BHF; -.
DR   PDBsum; 1BHH; -.
DR   PDBsum; 1CWD; -.
DR   PDBsum; 1CWE; -.
DR   PDBsum; 1FBZ; -.
DR   PDBsum; 1H92; -.
DR   PDBsum; 1IJR; -.
DR   PDBsum; 1KIK; -.
DR   PDBsum; 1LCJ; -.
DR   PDBsum; 1LCK; -.
DR   PDBsum; 1LKK; -.
DR   PDBsum; 1LKL; -.
DR   PDBsum; 1Q68; -.
DR   PDBsum; 1Q69; -.
DR   PDBsum; 1QPC; -.
DR   PDBsum; 1QPD; -.
DR   PDBsum; 1QPE; -.
DR   PDBsum; 1QPJ; -.
DR   PDBsum; 1X27; -.
DR   PDBsum; 2IIM; -.
DR   PDBsum; 2OF2; -.
DR   PDBsum; 2OF4; -.
DR   PDBsum; 2OFU; -.
DR   PDBsum; 2OFV; -.
DR   PDBsum; 2OG8; -.
DR   PDBsum; 2PL0; -.
DR   PDBsum; 2ZM1; -.
DR   PDBsum; 2ZM4; -.
DR   PDBsum; 2ZYB; -.
DR   PDBsum; 3AC1; -.
DR   PDBsum; 3AC2; -.
DR   PDBsum; 3AC3; -.
DR   PDBsum; 3AC4; -.
DR   PDBsum; 3AC5; -.
DR   PDBsum; 3AC8; -.
DR   PDBsum; 3ACJ; -.
DR   PDBsum; 3ACK; -.
DR   PDBsum; 3AD4; -.
DR   PDBsum; 3AD5; -.
DR   PDBsum; 3AD6; -.
DR   PDBsum; 3B2W; -.
DR   PDBsum; 3BRH; -.
DR   PDBsum; 3BYM; -.
DR   PDBsum; 3BYO; -.
DR   PDBsum; 3BYS; -.
DR   PDBsum; 3BYU; -.
DR   PDBsum; 3KMM; -.
DR   PDBsum; 3KXZ; -.
DR   PDBsum; 3LCK; -.
DR   PDBsum; 3MPM; -.
DR   PDBsum; 4C3F; -.
DR   PDBsum; 4D8K; -.
DR   PDBsum; 5MTM; -.
DR   PDBsum; 5MTN; -.
DR   PDBsum; 6H6A; -.
DR   PDBsum; 6PDJ; -.
DR   AlphaFoldDB; P06239; -.
DR   BMRB; P06239; -.
DR   SMR; P06239; -.
DR   BioGRID; 110124; 406.
DR   CORUM; P06239; -.
DR   DIP; DIP-553N; -.
DR   ELM; P06239; -.
DR   IntAct; P06239; 170.
DR   MINT; P06239; -.
DR   STRING; 9606.ENSP00000337825; -.
DR   BindingDB; P06239; -.
DR   ChEMBL; CHEMBL258; -.
DR   DrugBank; DB03023; 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine.
DR   DrugBank; DB07146; 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE.
DR   DrugBank; DB06925; 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE.
DR   DrugBank; DB07297; 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE.
DR   DrugBank; DB01830; AP-22408.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08056; N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine.
DR   DrugBank; DB08057; N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine.
DR   DrugBank; DB08055; N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugBank; DB04003; {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid.
DR   DrugCentral; P06239; -.
DR   GuidetoPHARMACOLOGY; 2053; -.
DR   iPTMnet; P06239; -.
DR   PhosphoSitePlus; P06239; -.
DR   SwissPalm; P06239; -.
DR   BioMuta; LCK; -.
DR   DMDM; 125474; -.
DR   CPTAC; CPTAC-1775; -.
DR   CPTAC; CPTAC-929; -.
DR   EPD; P06239; -.
DR   jPOST; P06239; -.
DR   MassIVE; P06239; -.
DR   MaxQB; P06239; -.
DR   PaxDb; P06239; -.
DR   PeptideAtlas; P06239; -.
DR   PRIDE; P06239; -.
DR   ProteomicsDB; 51874; -. [P06239-1]
DR   ProteomicsDB; 51875; -. [P06239-2]
DR   ProteomicsDB; 51876; -. [P06239-3]
DR   ABCD; P06239; 2 sequenced antibodies.
DR   Antibodypedia; 735; 1716 antibodies from 44 providers.
DR   DNASU; 3932; -.
DR   Ensembl; ENST00000333070.4; ENSP00000328213.4; ENSG00000182866.17. [P06239-3]
DR   Ensembl; ENST00000336890.10; ENSP00000337825.5; ENSG00000182866.17. [P06239-1]
DR   Ensembl; ENST00000619559.4; ENSP00000477713.1; ENSG00000182866.17. [P06239-1]
DR   GeneID; 3932; -.
DR   KEGG; hsa:3932; -.
DR   MANE-Select; ENST00000336890.10; ENSP00000337825.5; NM_005356.5; NP_005347.3.
DR   UCSC; uc001bux.3; human. [P06239-1]
DR   CTD; 3932; -.
DR   DisGeNET; 3932; -.
DR   GeneCards; LCK; -.
DR   HGNC; HGNC:6524; LCK.
DR   HPA; ENSG00000182866; Tissue enriched (lymphoid).
DR   MalaCards; LCK; -.
DR   MIM; 153390; gene.
DR   MIM; 615758; phenotype.
DR   neXtProt; NX_P06239; -.
DR   OpenTargets; ENSG00000182866; -.
DR   Orphanet; 280142; Severe combined immunodeficiency due to LCK deficiency.
DR   PharmGKB; PA30307; -.
DR   VEuPathDB; HostDB:ENSG00000182866; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000161163; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P06239; -.
DR   OMA; ICEHCNY; -.
DR   OrthoDB; 539311at2759; -.
DR   PhylomeDB; P06239; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P06239; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-167590; Nef Mediated CD4 Down-regulation.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-389948; PD-1 signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants.
DR   Reactome; R-HSA-9706374; FLT3 signaling through SRC family kinases.
DR   SignaLink; P06239; -.
DR   SIGNOR; P06239; -.
DR   BioGRID-ORCS; 3932; 17 hits in 1098 CRISPR screens.
DR   ChiTaRS; LCK; human.
DR   EvolutionaryTrace; P06239; -.
DR   GeneWiki; Lck; -.
DR   GenomeRNAi; 3932; -.
DR   Pharos; P06239; Tclin.
DR   PRO; PR:P06239; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P06239; protein.
DR   Bgee; ENSG00000182866; Expressed in thymus and 141 other tissues.
DR   ExpressionAtlas; P06239; baseline and differential.
DR   Genevisible; P06239; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0001772; C:immunological synapse; IDA:MGI.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051117; F:ATPase binding; IPI:UniProtKB.
DR   GO; GO:0042609; F:CD4 receptor binding; IPI:UniProtKB.
DR   GO; GO:0042610; F:CD8 receptor binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:ARUK-UCL.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0016004; F:phospholipase activator activity; IDA:ARUK-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:ARUK-UCL.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:CAFA.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0042608; F:T cell receptor binding; IPI:CAFA.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0006882; P:cellular zinc ion homeostasis; IEP:UniProtKB.
DR   GO; GO:0038094; P:Fc-gamma receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:ARUK-UCL.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903039; P:positive regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051249; P:regulation of lymphocyte activation; NAS:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0030217; P:T cell differentiation; IMP:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10362; SH2_Src_Lck; 1.
DR   CDD; cd12005; SH3_Lck; 1.
DR   DisProt; DP01580; -.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR035850; Lck_SH2.
DR   InterPro; IPR035749; Lck_SH3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Cytoplasm; Disease variant;
KW   Host-virus interaction; Kinase; Lipoprotein; Membrane; Myristate;
KW   Nucleotide-binding; Palmitate; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET        1
FT                   /note="Removed"
FT   CHAIN           2..509
FT                   /note="Tyrosine-protein kinase Lck"
FT                   /id="PRO_0000088124"
FT   DOMAIN          61..121
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          127..224
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          245..498
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          2..72
FT                   /note="Interactions with CD4 and CD8"
FT                   /evidence="ECO:0000250"
FT   REGION          154..242
FT                   /note="Interaction with PTPRH"
FT                   /evidence="ECO:0000269|PubMed:12837766"
FT   ACT_SITE        364
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         251..259
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         273
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         102
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         159
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         192
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P06240"
FT   MOD_RES         194
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         394
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8139546"
FT   MOD_RES         505
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000269|PubMed:1639064,
FT                   ECO:0000269|PubMed:8139546, ECO:0000269|PubMed:8631775,
FT                   ECO:0007744|PubMed:15592455, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000250"
FT   LIPID           3
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           5
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         321
FT                   /note="N -> NDTLLDSQLEEKGLGASPWGNLGQQLLLLPT (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_016049"
FT   VAR_SEQ         348..363
FT                   /note="IAEGMAFIEERNYIHR -> VRRLGRGAGQGNRPVT (in isoform
FT                   Short)"
FT                   /evidence="ECO:0000303|PubMed:7495859"
FT                   /id="VSP_005000"
FT   VAR_SEQ         364..509
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:7495859"
FT                   /id="VSP_005001"
FT   VARIANT         28
FT                   /note="V -> L (found in leukemia)"
FT                   /evidence="ECO:0000269|PubMed:8139546"
FT                   /id="VAR_013463"
FT   VARIANT         201
FT                   /note="G -> S (in dbSNP:rs11567841)"
FT                   /id="VAR_051697"
FT   VARIANT         232
FT                   /note="P -> PQKP (in leukemia)"
FT                   /id="VAR_013464"
FT   VARIANT         341
FT                   /note="L -> P (in IMD22; dbSNP:rs587777335)"
FT                   /evidence="ECO:0000269|PubMed:22985903"
FT                   /id="VAR_071291"
FT   VARIANT         353
FT                   /note="A -> V (found in leukemia)"
FT                   /evidence="ECO:0000269|PubMed:8139546"
FT                   /id="VAR_013465"
FT   VARIANT         447
FT                   /note="P -> L (found in leukemia)"
FT                   /evidence="ECO:0000269|PubMed:8139546"
FT                   /id="VAR_013466"
FT   MUTAGEN         59
FT                   /note="S->E: Allows interaction with SQSTM1."
FT                   /evidence="ECO:0000269|PubMed:8618896"
FT   MUTAGEN         154
FT                   /note="R->K: No effect on interaction with SQSTM1."
FT                   /evidence="ECO:0000269|PubMed:8618896"
FT   CONFLICT        29
FT                   /note="P -> R (in Ref. 2; AAA59502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        35
FT                   /note="T -> R (in Ref. 2; AAA59502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        87
FT                   /note="Q -> P (in Ref. 2; CAA31884/AAA59502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        206..211
FT                   /note="VRHYTN -> ASAITPI (in Ref. 1; CAA28691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        254
FT                   /note="G -> A (in Ref. 2; AAA59502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        258..267
FT                   /note="EVWMGYYNGH -> RCGWGTTTGT (in Ref. 1; CAA28691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        282..286
FT                   /note="PDAFL -> AGRLP (in Ref. 1; CAA28691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        375
FT                   /note="T -> A (in Ref. 14; CAA28165)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        472
FT                   /note="L -> H (in Ref. 13; CAA29667)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        504..509
FT                   /note="QYQPQP -> STA (in Ref. 1; CAA28691)"
FT                   /evidence="ECO:0000305"
FT   HELIX           12..15
FT                   /evidence="ECO:0007829|PDB:1Q68"
FT   STRAND          21..23
FT                   /evidence="ECO:0007829|PDB:1Q68"
FT   STRAND          24..27
FT                   /evidence="ECO:0007829|PDB:1Q69"
FT   TURN            60..63
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   STRAND          65..70
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   STRAND          76..79
FT                   /evidence="ECO:0007829|PDB:4D8K"
FT   STRAND          87..92
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   STRAND          95..102
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   TURN            103..105
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   STRAND          108..112
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   HELIX           113..115
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:2IIM"
FT   STRAND          128..131
FT                   /evidence="ECO:0007829|PDB:1CWD"
FT   HELIX           134..141
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   STRAND          151..155
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   STRAND          163..171
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   TURN            172..174
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   STRAND          175..185
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   TURN            187..189
FT                   /evidence="ECO:0007829|PDB:1LCJ"
FT   STRAND          191..194
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   STRAND          199..201
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   HELIX           202..211
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   STRAND          216..218
FT                   /evidence="ECO:0007829|PDB:1LKK"
FT   TURN            233..235
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:1QPE"
FT   HELIX           242..244
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          245..254
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          257..264
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   TURN            265..267
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          268..275
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   TURN            277..279
FT                   /evidence="ECO:0007829|PDB:1QPD"
FT   HELIX           282..294
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          303..307
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          313..317
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           324..327
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           331..334
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           338..357
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           367..369
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          370..372
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          378..380
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           383..385
FT                   /evidence="ECO:0007829|PDB:1QPE"
FT   HELIX           386..389
FT                   /evidence="ECO:0007829|PDB:3B2W"
FT   STRAND          390..392
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   STRAND          393..395
FT                   /evidence="ECO:0007829|PDB:4C3F"
FT   TURN            404..406
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           409..414
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           419..434
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   TURN            435..437
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           446..454
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           467..476
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           481..483
FT                   /evidence="ECO:0007829|PDB:1QPC"
FT   HELIX           487..500
FT                   /evidence="ECO:0007829|PDB:1QPC"
SQ   SEQUENCE   509 AA;  58001 MW;  44BFF0D43FFB420D CRC64;
     MGCGCSSHPE DDWMENIDVC ENCHYPIVPL DGKGTLLIRN GSEVRDPLVT YEGSNPPASP
     LQDNLVIALH SYEPSHDGDL GFEKGEQLRI LEQSGEWWKA QSLTTGQEGF IPFNFVAKAN
     SLEPEPWFFK NLSRKDAERQ LLAPGNTHGS FLIRESESTA GSFSLSVRDF DQNQGEVVKH
     YKIRNLDNGG FYISPRITFP GLHELVRHYT NASDGLCTRL SRPCQTQKPQ KPWWEDEWEV
     PRETLKLVER LGAGQFGEVW MGYYNGHTKV AVKSLKQGSM SPDAFLAEAN LMKQLQHQRL
     VRLYAVVTQE PIYIITEYME NGSLVDFLKT PSGIKLTINK LLDMAAQIAE GMAFIEERNY
     IHRDLRAANI LVSDTLSCKI ADFGLARLIE DNEYTAREGA KFPIKWTAPE AINYGTFTIK
     SDVWSFGILL TEIVTHGRIP YPGMTNPEVI QNLERGYRMV RPDNCPEELY QLMRLCWKER
     PEDRPTFDYL RSVLEDFFTA TEGQYQPQP
//
